Abnormal Proliferation
Conservative Site-specific Recombination and Phase Variation
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Induced Pluripotent Stem Cells
Combination Therapies and Personalized Medicine
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 16, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Kevin A Murgas1, Pons Materum2, Luke Z Li3
1Medical Scientist Training Program, Stony Brook University Renaissance School of Medicine, Stony Brook, NY 11794, USA.
Relapsed acute myeloid leukemia (AML) can acquire new genetic changes. This case highlights rare MYC and MECOM rearrangements emerging at relapse, stressing the need for ongoing monitoring in AML patients.
Area of Science:
Background: